ACYP1

Across TCGA pan-cancer cohorts, ACYP1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACYP1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACYP1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACYP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ACYP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.663	0.364	.002	32	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	23	view →
UCEC	OS	Median	All	0.835	0.981	.003	6	view →
HNSC	DFS	Quartile	All	0.338	0.855	.024	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →
LSCC	OS	Quartile	All	1.000	0.690	.042	3	view →
GBM	OS	Median	All	0.885	0.826	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACYP1–PDAC (OS)

Open the PDAC breakdown →